|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||35.32 - 35.77|
|52 Week Range||30.90 - 36.78|
|PE Ratio (TTM)||22.08|
|Forward Dividend & Yield||1.28 (3.61%)|
|1y Target Est||N/A|
Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental Pfizer Inc drug went about three months longer before their disease worsened than those who received chemotherapy in a late stage study, according to data released on Friday. The drug, talazoparib, a once daily pill that Pfizer acquired with its $14 billion purchase of Medivation, belongs to a class of medicines called PARP inhibitors that may induce tumor cell death. Patients in the Phase III study had mutations of the BRCA1/2 genes, the type of mutation that led actress Angelina Jolie to have preventive breast removal surgery.
In 3Q17, Eli Lilly’s (LLY) Humalog generated revenues of $696.2 million, ~9% growth on year-over-year (or YoY) basis and 3% growth on a quarter-over-quarter basis.
Allergan reported EPS of $4.15 on revenues of $4.03 billion in 3Q17, which was 11.4% higher YoY, compared with its revenues of $3.62 billion in 3Q16.
Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatment of ER+, HER2- metastatic breast cancer.
The promise of gene therapy to cure genetic diseases is underscored by a new article in The New England Journal of Medicine about a treatment for hemophilia B being developed by Spark Therapeutics (ONCE) and Pfizer (PFE). Spark and Pfizer have highlighted the article, which was based on previously reported data on 10 men who received the treatment and who were followed for about a year. The gene therapy uses a delivery system of neutered viruses to introduce healthy genes that code for the production of the clotting factor protein into the cells of patients with hemophilia B. A faulty gene caused by an inherited mutation prevents the production of that factor in hemophilia patients.
Rating Action: Moody's assigns A1 to Pfizer's new sterling notes; stable outlook. Global Credit Research- 07 Dec 2017. © 2017 Moody’ s Corporation, Moody’ s Investors Service, Inc., Moody’ s Analytics, ...
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence ...
All good things must come to an end, including the exclusivity of Pfizer’s prized little blue pill. On Dec. 11, some companies that manufacture generic pills will be allowed to start selling their own versions of Pfizer’s Viagra, and the New York-based pharmaceutical company is clinging to its potency pill with all its might. Rather…
Spark Therapeutics Inc. stock surged Wednesday afternoon after the company announced positive results from a study of a gene-therapy approach to hemophilia. The drug, developed and tested in a collaboration ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Pfizer Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
When AstraZeneca Plc paid $2.7 billion for an experimental drugmaker in 2015, it had its sights set on a potential blockbuster medicine. Instead, it got a Texas factory riddled with defects and two scathing ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pfizer Inc. Here are 5 ETFs with the largest exposure to PFE-US. Comparing the performance and risk of Pfizer Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Troy Hunt has collected a trove of 4.8 billion stolen identity records pulled from the darkest corners of the internet — but he isn't a hacker.
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first generic competition next week.